Anti-Müllerian hormone ameliorates uterine DNA damage response and prevents pregnancy complications in doxorubicin-treated mice
Biology of Reproduction · 16.03.2026 · 114 (3) · 855-870
DOI: 10.1093/biolre/ioaf233 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biology of Reproduction, online erschienen am 17.10.2025. Verfasst von Ngoc Minh Phuong Nguyen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Surgical Research Laboratories, Massachusetts General Hospital, Boston, MA, USA. Hauptthemen laut MEDLINE: Doxorubicin, DNA Damage, Anti-Mullerian Hormone, Uterus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS.
Abstract (Originalsprache)
Anti-Müllerian hormone is a promising fertoprotective agent, demonstrating particularly strong efficacy against doxorubicin-induced ovarian toxicity. However, the impact of chemotherapy on the uterus, and the potential benefits of anti-Müllerian hormone in this context, remain poorly understood. In this study, we characterized doxorubicin-induced uterine damage and assessed the fertoprotective effect of anti-Müllerian hormone co-treatment in mice. Acutely, doxorubicin treatment caused the accumulation of DNA damage in multiple uterine cell-types, including the myometrium, as evidenced by both increased γ-H2AX staining and upregulation of Cdkn1a, Trp53, and other downstream Trp53 pathway targets, both at the mRNA and protein levels. Anti-Müllerian hormone co-treatment counteracted these effects by reducing γ-H2AX-positive DNA damage lesion accumulation and by suppressing Trp53 and its downstream pathway. Furthermore, anti-Müllerian hormone co-treatment significantly reduced the incidence of doxorubicin-induced labor dystocia, a complication of parturition, in pregnancies following chemotherapy treatment. These findings suggest that, in addition to ovarian protection, anti-Müllerian hormone may have benefits in preserving myometrial integrity and long-term uterine function following chemotherapy, further supporting its therapeutic potential for fertility preservation in cancer patients receiving chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Surgical Research Laboratories, Massachusetts General Hospital, Boston, MA, USA.
- Department of Surgery, Harvard Medical School, Boston, MA, USA.
ORCID-Profile: Marie-Charlotte Meinsohn, David Pepin
Förderung
- NICHD NIH HHS
Zitieren
APA
Nguyen, N. M. P., Mermin-Bunnell, A. M., de Mattos, K., Cleverdon, J., Kano, M., Chauvin, M., Godin, P., Kashiwagi, A., Duong, T., Nagykery, N., Donahoe, P. K., Meinsohn, M. C., & Pepin, D. (2026). Anti-Müllerian hormone ameliorates uterine DNA damage response and prevents pregnancy complications in doxorubicin-treated mice. Biology of Reproduction, 114(3), 855-870. https://doi.org/10.1093/biolre/ioaf233
Vancouver
Nguyen NMP, Mermin-Bunnell AM, de Mattos K, Cleverdon J, Kano M, Chauvin M, et al. Anti-Müllerian hormone ameliorates uterine DNA damage response and prevents pregnancy complications in doxorubicin-treated mice. Biology of Reproduction. 2026;114(3):855-870. doi:10.1093/biolre/ioaf233
BibTeX
@article{Nguyen2026,
author = {Nguyen, Ngoc Minh Phuong and Mermin-Bunnell, Alana M and de Mattos, Karine and Cleverdon, Josephine and Kano, Motohiro and Chauvin, Maeva and Godin, Philippe and Kashiwagi, Aki and Duong, Thy and Nagykery, Nicholas and Donahoe, Patricia K and Meinsohn, Marie-Charlotte and Pepin, David},
title = {Anti-Müllerian hormone ameliorates uterine DNA damage response and prevents pregnancy complications in doxorubicin-treated mice},
journal = {Biology of Reproduction},
year = {2026},
volume = {114},
number = {3},
pages = {855--870},
doi = {10.1093/biolre/ioaf233}
}
EUVIMED